IL142958A0 - Vitronectin receptor antagonist pharmaceuticals - Google Patents
Vitronectin receptor antagonist pharmaceuticalsInfo
- Publication number
- IL142958A0 IL142958A0 IL14295899A IL14295899A IL142958A0 IL 142958 A0 IL142958 A0 IL 142958A0 IL 14295899 A IL14295899 A IL 14295899A IL 14295899 A IL14295899 A IL 14295899A IL 142958 A0 IL142958 A0 IL 142958A0
- Authority
- IL
- Israel
- Prior art keywords
- receptor antagonist
- vitronectin receptor
- antagonist pharmaceuticals
- pharmaceuticals
- vitronectin
- Prior art date
Links
- 102100022337 Integrin alpha-V Human genes 0.000 title 1
- 108010048673 Vitronectin Receptors Proteins 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
- A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Radiology & Medical Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acoustics & Sound (AREA)
- Optics & Photonics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11273298P | 1998-12-18 | 1998-12-18 | |
PCT/US1999/030315 WO2000035492A2 (fr) | 1998-12-18 | 1999-12-17 | Medicaments antagonistes du recepteur de la vitronectine |
Publications (1)
Publication Number | Publication Date |
---|---|
IL142958A0 true IL142958A0 (en) | 2002-04-21 |
Family
ID=22345571
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL14295899A IL142958A0 (en) | 1998-12-18 | 1999-12-17 | Vitronectin receptor antagonist pharmaceuticals |
IL142958A IL142958A (en) | 1998-12-18 | 2001-05-03 | Vitronectin receptor antagonist pharmaceuticals |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL142958A IL142958A (en) | 1998-12-18 | 2001-05-03 | Vitronectin receptor antagonist pharmaceuticals |
Country Status (12)
Country | Link |
---|---|
US (4) | US6511648B2 (fr) |
EP (1) | EP1140204A2 (fr) |
JP (1) | JP2002532440A (fr) |
CN (1) | CN1356913A (fr) |
AU (1) | AU766822B2 (fr) |
BR (1) | BR9917079A (fr) |
CA (2) | CA2727746A1 (fr) |
HK (1) | HK1047694A1 (fr) |
IL (2) | IL142958A0 (fr) |
NZ (1) | NZ511677A (fr) |
WO (1) | WO2000035492A2 (fr) |
ZA (1) | ZA200103675B (fr) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2727746A1 (fr) | 1998-12-18 | 2000-06-22 | Bristol-Myers Squibb Pharma Company | Medicaments antagonistes du recepteur de la vitronectine de quinolone |
US6511649B1 (en) * | 1998-12-18 | 2003-01-28 | Thomas D. Harris | Vitronectin receptor antagonist pharmaceuticals |
TR200102524T2 (tr) * | 1999-03-03 | 2002-02-21 | The Procter & Gamble Company | Dihetero sübstitüe edilmiş metaloproteaz inhibitörleri. |
IL152941A0 (en) * | 2000-06-21 | 2003-06-24 | Bristol Myers Squibb Co | Fused heterocyclic compounds and kits and pharmaceutical compositions containing the same |
DE10135315A1 (de) * | 2001-07-19 | 2003-01-30 | Bayer Ag | Stents |
JP2004537573A (ja) * | 2001-08-08 | 2004-12-16 | ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー | 心臓灌流およびビトロネクチン受容体を標的とするイメージング剤の同時イメージング |
US7279150B2 (en) | 2002-01-24 | 2007-10-09 | Barnes-Jewish Hospital | Chelating agents with lipophilic carriers |
NZ534500A (en) | 2002-01-24 | 2007-07-27 | Barnes Jewish Hospital | Nanoparticle-based emulsions specifically targeted to integrins |
US7344704B2 (en) | 2002-07-10 | 2008-03-18 | Schering Ag | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of intravascular thrombi |
US6961607B2 (en) * | 2002-07-31 | 2005-11-01 | Uzgiris Egidijus E | Method for assessing myocardial angiogenesis |
US20040224986A1 (en) | 2002-08-16 | 2004-11-11 | Bart De Corte | Piperidinyl targeting compounds that selectively bind integrins |
ATE449614T1 (de) * | 2003-05-12 | 2009-12-15 | Lantheus Medical Imaging Inc | Vitronectin rezeptorantagonisten und ihre verwendung als radiopharmazeutika |
WO2005016387A2 (fr) * | 2003-08-12 | 2005-02-24 | University Of Iowa Research Foundation | Agents de contraste mri dependant d'adn |
US20050136003A1 (en) * | 2003-10-31 | 2005-06-23 | Casebier David S. | Novel chemical agents comprising a cardiotonic moiety and an imaging moiety and methods of their use |
US20050106101A1 (en) * | 2003-10-31 | 2005-05-19 | Ajay Purohit | Novel chemical agents comprising an adenosine moiety or an adenosine analog moiety and an imaging moiety and methods of their use |
US7504088B2 (en) | 2004-06-09 | 2009-03-17 | Kereos, Inc. | Lipophilic derivatives of chelate monoamides |
EP1793868B1 (fr) * | 2004-09-23 | 2010-12-29 | Guerbet | Agents de contraste liposomaux pour technologie d'imagerie cest |
US20060083681A1 (en) * | 2004-10-18 | 2006-04-20 | Ajay Purohit | Compounds for myocardial perfusion imaging |
US8926945B2 (en) * | 2005-10-07 | 2015-01-06 | Guerbet | Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium |
US8986650B2 (en) | 2005-10-07 | 2015-03-24 | Guerbet | Complex folate-NOTA-Ga68 |
EP2094311A4 (fr) * | 2006-10-24 | 2013-04-10 | Kereos Inc | Lieurs améliorés pour ancrer des ligands de ciblage |
TWI618544B (zh) | 2006-12-26 | 2018-03-21 | 藍瑟斯醫學影像公司 | 使心臟神經分布顯像之配位體 |
US20100178245A1 (en) * | 2009-01-13 | 2010-07-15 | Arnsdorf Morton F | Biocompatible Microbubbles to Deliver Radioactive Compounds to Tumors, Atherosclerotic Plaques, Joints and Other Targeted Sites |
FR2942227B1 (fr) | 2009-02-13 | 2011-04-15 | Guerbet Sa | Utilisation de tampons pour la complexation de radionucleides |
KR102008635B1 (ko) | 2010-05-11 | 2019-08-07 | 랜티우스 메디컬 이메징, 인크. | 영상화제의 합성 및 사용을 위한 조성물, 방법 및 시스템 |
FR2968999B1 (fr) | 2010-12-20 | 2013-01-04 | Guerbet Sa | Nanoemulsion de chelate pour irm |
TWI700268B (zh) | 2011-09-09 | 2020-08-01 | 美商藍瑟斯醫學影像公司 | 用於合成及使用造影劑之組合物、方法及系統 |
FR2980364B1 (fr) | 2011-09-26 | 2018-08-31 | Guerbet | Nanoemulsions et leur utilisation comme agents de contraste |
ES2748940T3 (es) | 2011-11-11 | 2020-03-18 | Univ Yale | Evaluación de la presencia de una fibrilación auricular y de la vulnerabilidad a ésta, y otras indicaciones sobre la base de la toma de imágenes basada en metaloproteinasas de matriz |
AU2013203000B9 (en) | 2012-08-10 | 2017-02-02 | Lantheus Medical Imaging, Inc. | Compositions, methods, and systems for the synthesis and use of imaging agents |
FR3001154B1 (fr) | 2013-01-23 | 2015-06-26 | Guerbet Sa | Magneto-emulsion vectorisee |
RS62591B1 (sr) | 2013-09-24 | 2021-12-31 | Fujifilm Corp | Novo jedinjenje koje sadrži azot ili njegova so ili njihov kompleks sa metalom |
WO2015179963A1 (fr) * | 2014-05-29 | 2015-12-03 | Uti Limited Partnership | Dendrimères polyanioniques et non ioniques à base de cyclodextrine |
CN107428755B (zh) | 2015-03-25 | 2020-03-03 | 富士胶片株式会社 | 含氮化合物或其盐的制造方法以及它们的制造中间体 |
WO2020007822A1 (fr) | 2018-07-02 | 2020-01-09 | Conservatoire National Des Arts Et Metiers (Cnam) | Nanoparticules de bismuth métallique (0), procédé de fabrication et utilisations de celles-ci |
Family Cites Families (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4248802A (en) | 1975-06-20 | 1981-02-03 | Rhone-Poulenc Industries | Catalytic hydroformylation of olefins |
WO1981001145A1 (fr) | 1979-10-18 | 1981-04-30 | Univ Illinois | Medicaments "pro-drugs" pouvant etre actives par des enzymes hydrolytiques |
US4859777A (en) | 1981-07-01 | 1989-08-22 | Eastman Kodak Company | Terpyridine chelating agents |
US4957939A (en) | 1981-07-24 | 1990-09-18 | Schering Aktiengesellschaft | Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging |
DE3360633D1 (en) | 1982-02-12 | 1985-10-03 | Unitika Ltd | Anti-cancer device |
US4452774A (en) | 1982-04-30 | 1984-06-05 | President And Fellows Of Harvard College | Isonitrile radionuclide complexes for labelling and imaging agents |
US4472509A (en) | 1982-06-07 | 1984-09-18 | Gansow Otto A | Metal chelate conjugated monoclonal antibodies |
EP0247156B1 (fr) | 1985-11-18 | 1993-06-23 | Access Pharmaceuticals Inc. | Agents polychelateurs pour l'amelioration de l'image et du spectre (et pour derive spectrale) |
CA1305160C (fr) | 1985-12-23 | 1992-07-14 | Paul Louis Bergstein | Isonitriles de type ether et complexes radioetiquettes de ceux-ci |
MX174467B (es) | 1986-01-23 | 1994-05-17 | Squibb & Sons Inc | 1,4,7-triscarboximetil-1,4,7,10-tetraazaciclodo decano substituido en 1 y compuestos analogos |
US5252317A (en) | 1986-11-10 | 1993-10-12 | The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon | Amplifier molecules for diagnosis and therapy derived from 3,5-bis[1-(3-amino-2,2-bis (aminomethyl)-propyl) oxymethyl] benzoic acid |
US5567411A (en) | 1986-11-10 | 1996-10-22 | State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon | Dendritic amplifier molecules having multiple terminal active groups stemming from a benzyl core group |
US5064956A (en) | 1987-06-24 | 1991-11-12 | The Dow Chemical Company | Process for preparing mono-n-alkylated polyazamacrocycles |
US5135736A (en) | 1988-08-15 | 1992-08-04 | Neorx Corporation | Covalently-linked complexes and methods for enhanced cytotoxicity and imaging |
IL91933A (en) | 1988-10-11 | 1994-12-29 | Univ Southern California | Their immuno-bracelet and isophiles which are beneficial in increasing vascular permeability or blood supply to tumor or otherwise damaged tissue |
AU636589B2 (en) | 1988-11-14 | 1993-05-06 | Brigham And Women's Hospital | Antibodies specific for elam-1 and the use thereof |
US5376356A (en) | 1989-03-14 | 1994-12-27 | Neorx Corporation | Imaging tissue sites of inflammation |
IL112767A (en) | 1989-04-10 | 1998-01-04 | Oncogen | Pharmaceutical compositions containing oncostatin m |
US5272263A (en) | 1989-04-28 | 1993-12-21 | Biogen, Inc. | DNA sequences encoding vascular cell adhesion molecules (VCAMS) |
US5395609A (en) | 1989-06-19 | 1995-03-07 | Antisoma Limited | Synthetic peptides for use in tumor detection |
WO1991001144A1 (fr) | 1989-07-20 | 1991-02-07 | Sandoz Ltd | Derives de polypeptide etiquetes |
US5087440A (en) | 1989-07-31 | 1992-02-11 | Salutar, Inc. | Heterocyclic derivatives of DTPA used for magnetic resonance imaging |
GB8923843D0 (en) | 1989-10-23 | 1989-12-13 | Salutar Inc | Compounds |
US5679810A (en) | 1990-01-19 | 1997-10-21 | Salutar, Inc. | Linear oligomeric polychelant compounds |
GB9006977D0 (en) | 1990-03-28 | 1990-05-23 | Nycomed As | Compositions |
WO1992017215A1 (fr) | 1990-03-28 | 1992-10-15 | Nycomed Salutar, Inc. | Milieux de contraste |
IN172208B (fr) | 1990-04-02 | 1993-05-01 | Sint Sa | |
TW212184B (fr) | 1990-04-02 | 1993-09-01 | Takeda Pharm Industry Co Ltd | |
US5382654A (en) | 1992-02-05 | 1995-01-17 | Mallinckrodt Medical, Inc. | Radiolabelled peptide compounds |
JPH06505253A (ja) | 1991-01-24 | 1994-06-16 | サイテル コーポレイション | Elam−1に対するモノクロナール抗体及びそれらの使用 |
US5504064A (en) | 1991-04-10 | 1996-04-02 | Oklahoma Medical Research Foundation | Treatment of bleeding with modified tissue factor in combination with an activator of FVII |
CA2109527A1 (fr) | 1991-05-03 | 1992-11-04 | Elaine Tuomanen | Homologies de sequence d'acides amines entre des selectines et la toxine de b. pertussis, peptides derives, anticorps diriges contre eux et compositions pharmaceutiques en contenant |
WO1993008210A1 (fr) | 1991-10-18 | 1993-04-29 | Beth Israel Hospital Association | Composes cibles sur le facteur de permeabilite vasculaire |
US5660827A (en) | 1992-03-05 | 1997-08-26 | Board Of Regents, The University Of Texas System | Antibodies that bind to endoglin |
US5965132A (en) | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
DK0627940T3 (da) | 1992-03-05 | 2003-09-01 | Univ Texas | Anvendelse af immunokonjugater til diagnose og/eller terapi af vaskulariserede tumorer |
GB9209641D0 (en) | 1992-05-02 | 1992-06-17 | Johnson Matthey Plc | Improvements in radiolabelling |
AU5093593A (en) | 1992-08-28 | 1994-03-29 | Scripps Research Institute, The | Inhibition of tumor metastasis via neutralization of tissue factor function |
CN1701814A (zh) | 1992-11-13 | 2005-11-30 | 马克斯普朗克科学促进协会 | 作为血管内皮生长因子受体的f1k-1 |
US5342757A (en) | 1992-11-13 | 1994-08-30 | Ludwig Institute For Cancer Research | Monoclonal antibodies which specifically binds to endosialin, a 165 Kd glycoprotein found on tumor vascular endothelium, and uses thereof |
US5650134A (en) | 1993-01-12 | 1997-07-22 | Novartis Ag (Formerly Sandoz Ltd.) | Peptides |
DE4301871A1 (de) | 1993-01-13 | 1994-07-14 | Diagnostikforschung Inst | Neue Mittel zur Diagnose von Gefäßerkrankungen |
US5760191A (en) | 1993-02-05 | 1998-06-02 | Nycomed Imaging As | Macrocyclic complexing agents and targeting immunoreagents useful in therapeutic and diagnostic compositions and methods |
US5744120A (en) | 1993-03-30 | 1998-04-28 | The Dupont Merick Pharmaceutical Company | Ternary radiopharmaceutical complexes |
US5750088A (en) | 1993-03-30 | 1998-05-12 | The Dupont Merck Pharmaceutical Company | Stable hydrazones linked to a peptide moiety as reagents for the preparation of radiopharmaceuticals |
DE4311023C2 (de) | 1993-03-31 | 1996-05-02 | Diagnostikforschung Inst | Bifunktionelle chalkogenatom-unterbrochene Chelatbildner von Typ XN¶1¶S¶1¶O¶1¶ für radioaktive Isotope, deren Metallkomplexe, Verfahren zu ihrer Herstellung sowie diese enthaltende pharmazeutische Mittel |
DE69408145T2 (de) | 1993-07-19 | 1998-09-03 | Resolution Pharm Inc | Hydrazine mit einer n3s konfiguration als radionukleide chelatoren |
US5417959A (en) | 1993-10-04 | 1995-05-23 | Mallinckrodt Medical, Inc. | Functionalized aza-crytand ligands for diagnostic imaging applications |
US5753230A (en) | 1994-03-18 | 1998-05-19 | The Scripps Research Institute | Methods and compositions useful for inhibition of angiogenesis |
ZA955391B (en) | 1994-06-29 | 1996-02-09 | Smithkline Beecham Corp | Vitronectin receptor antagonists |
EP0771216B9 (fr) | 1994-07-11 | 2003-01-02 | The Board Of Regents, The University Of Texas System | Procedes et compositions pour la coagulation specifique de vaisseaux tumoraux |
JP3465367B2 (ja) * | 1994-08-23 | 2003-11-10 | 東陶機器株式会社 | イオンリッチ水生成装置 |
US5556939A (en) | 1994-10-13 | 1996-09-17 | Merck Frosst Canada, Inc. | TC or RE radionuclide labelled chelate, hexapeptide complexes useful for diagnostic or therapeutic applications |
US5520904A (en) | 1995-01-27 | 1996-05-28 | Mallinckrodt Medical, Inc. | Calcium/oxyanion-containing particles with a polymerical alkoxy coating for use in medical diagnostic imaging |
EP0727225A3 (fr) | 1995-02-14 | 1997-01-15 | Sonus Pharma Inc | Compositions et méthodes pour l'imagerie ultrasonique dirigée |
US5801228A (en) | 1995-06-07 | 1998-09-01 | Nycomed Imaging As | Polymeric contrast agents for medical imaging |
DE69632401T2 (de) * | 1995-06-07 | 2005-05-19 | Imarx Pharmaceutical Corp., Tucson | Neue zielgerichtete mittel zur diagnostischen und therapeutischen verwendung |
GB9511989D0 (en) | 1995-06-13 | 1995-08-09 | Glaxo Group Ltd | Chemical compounds |
CA2230209A1 (fr) | 1995-08-30 | 1997-03-06 | G.D. Searle & Co. | Derives de la meta-guanidine, de l'uree, de la thio-uree ou de l'acide aminobenzoique azacyclique utilises comme antagonistes de l'integrine |
DE19536781A1 (de) | 1995-09-21 | 1997-03-27 | Diagnostikforschung Inst | Bifunktionelle sulfidhaltige Sulfonamid-Chelatbildner vom Typ XSNS für radioaktive Isotope |
DE19536785A1 (de) | 1995-09-21 | 1997-03-27 | Diagnostikforschung Inst | Bifunktionelle sulfidhaltige Sulfonamid-Chelatbildner vom Typ S¶2¶NY für radioaktive Isotope |
JP4018141B2 (ja) | 1995-11-01 | 2007-12-05 | ブラッコ・リサーチ・ソシエテ・アノニム | Nmr画像形成用の標的磁気標識分子マーカーシステム |
SI9620120A (sl) | 1995-11-14 | 1999-06-30 | Dupont Pharmaceuticals Company | Nove makrociklične spojine kot metaloproteazni inhibitorji |
JP2000501105A (ja) | 1995-12-22 | 2000-02-02 | デュポン ファーマシューティカルズ カンパニー | 新規なインテグリン受容体アンタゴニスト |
US5804161A (en) | 1996-05-14 | 1998-09-08 | Nycomed Salutar Inc. | Contrast agents |
ZA978758B (en) | 1996-10-02 | 1999-03-30 | Du Pont Merck Pharma | Technetium-99m-labeled chelator incorporated cyclic peptides that bind to the GPIIb/IIIa receptor as imaging agents |
US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
WO1998016256A1 (fr) * | 1996-10-16 | 1998-04-23 | The Burnham Institute | Imagerie par resonance magnetique utilisee detecter un thrombus |
GB9708265D0 (en) | 1997-04-24 | 1997-06-18 | Nycomed Imaging As | Contrast agents |
WO1998018495A2 (fr) * | 1996-10-28 | 1998-05-07 | Marsden, John, Christopher | Ameliorations apportees a des agents diagnostiques et/ou therapeutiques ou les concernant |
WO1998018497A2 (fr) | 1996-10-28 | 1998-05-07 | Nycomed Imaging As | Agents de contraste |
ATE342262T1 (de) | 1996-11-27 | 2006-11-15 | Bristol Myers Squibb Pharma Co | Neue integrin rezeptor antagonisten |
US6245318B1 (en) * | 1997-05-27 | 2001-06-12 | Mallinckrodt Inc. | Selectively binding ultrasound contrast agents |
DE19725368A1 (de) | 1997-06-16 | 1998-12-17 | Merck Patent Gmbh | Cyclische Adhäsionsinhibitoren und deren Verwendung für bildgebende Verfahren |
WO1999006049A1 (fr) * | 1997-08-04 | 1999-02-11 | Smithkline Beecham Corporation | Antagonistes du recepteur de l'integrine |
WO1999013329A1 (fr) | 1997-09-10 | 1999-03-18 | The Burnham Institute | Procedes relatifs a l'identification de molecules capables de rallier des systemes vasculaires angiogeniques dans les tumeurs |
CA2320339A1 (fr) | 1998-02-11 | 1999-08-19 | Resolution Pharmaceuticals Inc. | Molecules ciblant l'angiogenese |
US6093382A (en) | 1998-05-16 | 2000-07-25 | Bracco Research Usa Inc. | Metal complexes derivatized with folate for use in diagnostic and therapeutic applications |
CA2338275A1 (fr) | 1998-07-29 | 2000-02-10 | Merck & Co., Inc. | Antagonistes des recepteurs de l'integrine |
CA2727746A1 (fr) * | 1998-12-18 | 2000-06-22 | Bristol-Myers Squibb Pharma Company | Medicaments antagonistes du recepteur de la vitronectine de quinolone |
WO2001097861A2 (fr) | 2000-06-21 | 2001-12-27 | Bristol-Myers Squibb Pharma Company | Agents pharmaceutiques antagonistes du recepteur de la vitronectine destines a etre utilises dans une therapie combinee |
JP2005538030A (ja) | 2000-06-21 | 2005-12-15 | デュポン ファーマシューティカルズ カンパニー | 組み合わせ療法での使用のための血管新生障害の画像診断用医薬 |
AU7002501A (en) | 2000-06-21 | 2002-01-02 | Du Pont Pharm Co | Vitronectin receptor antagonist pharmaceuticals for use in combination therapy |
EP1311301A2 (fr) | 2000-07-06 | 2003-05-21 | Bristol-Myers Squibb Pharma Company | Compositions radiopharmaceutiques stables et procedes de fabrication de ces compositions |
-
1999
- 1999-12-17 CA CA2727746A patent/CA2727746A1/fr not_active Abandoned
- 1999-12-17 BR BR9917079-5A patent/BR9917079A/pt not_active Application Discontinuation
- 1999-12-17 CA CA002349501A patent/CA2349501A1/fr not_active Abandoned
- 1999-12-17 US US09/465,300 patent/US6511648B2/en not_active Expired - Fee Related
- 1999-12-17 AU AU23716/00A patent/AU766822B2/en not_active Ceased
- 1999-12-17 EP EP99967443A patent/EP1140204A2/fr not_active Withdrawn
- 1999-12-17 WO PCT/US1999/030315 patent/WO2000035492A2/fr not_active Application Discontinuation
- 1999-12-17 JP JP2000587811A patent/JP2002532440A/ja active Pending
- 1999-12-17 IL IL14295899A patent/IL142958A0/xx active IP Right Grant
- 1999-12-17 NZ NZ511677A patent/NZ511677A/en unknown
- 1999-12-17 CN CN99814567A patent/CN1356913A/zh active Pending
-
2001
- 2001-05-03 IL IL142958A patent/IL142958A/en not_active IP Right Cessation
- 2001-05-07 ZA ZA200103675A patent/ZA200103675B/en unknown
- 2001-09-07 US US09/947,783 patent/US6743412B2/en not_active Expired - Fee Related
- 2001-09-07 US US09/948,807 patent/US6683163B2/en not_active Expired - Fee Related
- 2001-09-07 US US09/948,390 patent/US6689337B2/en not_active Expired - Fee Related
-
2002
- 2002-10-31 HK HK02107922.6A patent/HK1047694A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CA2727746A1 (fr) | 2000-06-22 |
AU766822B2 (en) | 2003-10-23 |
CN1356913A (zh) | 2002-07-03 |
EP1140204A2 (fr) | 2001-10-10 |
US20020182147A1 (en) | 2002-12-05 |
US6743412B2 (en) | 2004-06-01 |
BR9917079A (pt) | 2001-10-30 |
AU2371600A (en) | 2000-07-03 |
IL142958A (en) | 2006-12-31 |
US20030232053A1 (en) | 2003-12-18 |
US6683163B2 (en) | 2004-01-27 |
US6689337B2 (en) | 2004-02-10 |
US6511648B2 (en) | 2003-01-28 |
HK1047694A1 (zh) | 2003-03-07 |
US20020041878A1 (en) | 2002-04-11 |
ZA200103675B (en) | 2002-06-07 |
JP2002532440A (ja) | 2002-10-02 |
CA2349501A1 (fr) | 2000-06-22 |
WO2000035492A3 (fr) | 2001-01-18 |
NZ511677A (en) | 2003-10-31 |
US20020061909A1 (en) | 2002-05-23 |
WO2000035492A2 (fr) | 2000-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL142958A0 (en) | Vitronectin receptor antagonist pharmaceuticals | |
EP1000031A4 (fr) | Antagonistes du recepteur de vitronectine | |
AP9901493A0 (en) | Vitronectin receptor antagonists | |
IL130760A0 (en) | Vitronectin receptor antagonists | |
IL135189A0 (en) | Vitronectin receptor antagonist | |
AU2371400A (en) | Vitronectin receptor antagonist pharmaceuticals | |
PL342881A1 (en) | Vitronectin receptor antagonists | |
IL135188A0 (en) | Vitronectin receptor antagonist | |
AU2001271435A1 (en) | Vitronectin receptor antagonist pharmaceuticals | |
IL135028A0 (en) | Vitronectin receptor antagonists | |
EG24025A (en) | Vitronectin receptor antagonist | |
GC0000203A (en) | Vitronectin receptor antagonists | |
PL346157A1 (en) | Vitronectin receptor antagonists | |
SI1140203T1 (sl) | Viktronektin receptor farmacevtski antagonist | |
GB9822331D0 (en) | Vitronectin receptor antagonists | |
GB9807384D0 (en) | Vitronectin receptor antagonists | |
GB9807382D0 (en) | Vitronectin receptor antagonists | |
GB9815803D0 (en) | Vitronectin receptor antagonists | |
GB9812686D0 (en) | Vitronectin receptor antagonists | |
GB9811295D0 (en) | Vitronectin receptor antagonists | |
GB9810892D0 (en) | Vitronectin receptor antagonists | |
GB9810882D0 (en) | Vitronectin receptor antagonists | |
GB9810182D0 (en) | Vitronectin receptor antagonists | |
ZA988562B (en) | Vitronectin receptor antagonists | |
ZA991884B (en) | Vitronectin receptor antagonists. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed |